InvestSMART

AnteoTech Limited (ASX:ADO)

ALERT: Price-sensitive ASX Announcement for ADO
Current share price for ADO : $0.014 -0.005 (-26.32%)+
Announcement
Release
31 Aug 2026 9:29AM
Price at Release
$0.019
Full Release
download
Summary
AnteoTech Ltd’s Appendix 4E preliminary final report presents unaudited consolidated financial statements for the Australian financial year ended 30 June 2026, showing revenue from contracts with customers of $467,589, other income of $2,598,354 including an R&D tax concession of $2,588,632, total revenue and other income of $3,129,144, and a reduced net loss after tax attributable to shareholders of $4,928,074 compared with $6,759,135 in FY2025; the company reported no dividends, net tangible assets of 0.36 cents per share, cash at bank of $5.70 million plus a $5.50 million six-month term deposit maturing 18 December 2026, and materially strengthened its balance sheet through a $3.81 million share placement and the full exercise of listed ADOO options raising $10.03 million before costs, lifting net assets to $11.80 million; management noted lower operating costs following strategic review actions, ongoing recurring Life Sciences revenue including its supply arrangement with Serum Institute of India, commercial progress in Advanced Battery Technologies, the extension of the first ARENA milestone to November 2026, and the withdrawal from the Queensland Critical Minerals and Battery Technology Fund, while also stating that although the accounts are prepared on a going concern basis, material uncertainty remains because the group is still loss-making and future funding, sales growth and commercialisation success are important to ongoing operations.
Key Points
  • Appendix 4E preliminary final report for the year ended 30 June 2026 is unaudited.
  • AnteoTech Ltd is the reporting entity and is listed on the ASX under ticker ADO.
  • Revenue from ordinary activities fell 52% to $467,589.
  • Interest and other income from ordinary activities rose 7% to $2,661,555.
  • Total revenue and other income decreased 10% to $3,129,144.
  • Loss after tax attributable to owners improved 27% to $4,928,074.
  • No dividends were paid, recommended or declared for FY2026.
  • Net tangible assets per ordinary security increased to 0.36 cents from 0.12 cents.
  • Revenue included product sales and contract services across Life Sciences and Advanced Battery Technologies.
  • The FY2026 R&D tax concession recognised was $2,588,632.
  • The company continued recurring Life Sciences revenue under its five-year take-or-pay agreement with Serum Institute of India.
  • A shipment of $134,138 of AnteoBind to Serum Institute of India in July 2026 will be recognised in FY2027.
  • Total expenses excluding depreciation, amortisation and share-based payments fell by $2,040,807 year-on-year.
  • Lower costs were mainly due to reduced salaries and wages, professional services, director fees and research expenses.
  • All listed ADOO options were exercised at 3.5 cents, raising $10,032,004 before costs.
  • AnteoTech also raised $3,808,350 through a share placement in January and February 2026 at 1.55 cents per share with an attaching option.
  • Cash on hand at 30 June 2026 was $5,700,745.
  • The company also held a $5,500,000 six-month term deposit maturing on 18 December 2026.
  • Total assets increased to $15,398,646 and net assets increased to $11,798,538.
  • Contributed equity rose to $116,831,193.
  • The company remains loss-making but the accounts were prepared on a going concern basis.
  • Directors acknowledged a material uncertainty that may cast significant doubt on going concern absent future funding and successful commercialisation.
  • Commercial progress highlighted included battery opportunities with Black Diamond Structures, Xerabrid and Wyon AG.
  • The first milestone date under AnteoTech’s up to $4,000,000 ARENA funding agreement was extended to November 2026.
  • The company withdrew from its funding agreement with the Queensland Critical Minerals and Battery Technology Fund.
  • The company expects to lodge audited financial statements for the year ended 30 June 2026 by 30 September 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.